AC Immune SA (ACIU) Stock Forecast, Price Target & Predictions
ACIU Stock Forecast
AC Immune SA stock forecast is as follows: an average price target of $9.00 (represents a 235.82% upside from ACIU’s last price of $2.68) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ACIU Price Target
The average price target for AC Immune SA (ACIU) is $9.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $8.00. This represents a potential 235.82% upside from ACIU's last price of $2.68.
ACIU Analyst Ratings
According to 3 Wall Street analysts, AC Immune SA's rating consensus is 'Buy'. The analyst rating breakdown for ACIU stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
AC Immune SA Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 30, 2024 | Thomas Shrader | BTIG | $8.00 | $3.97 | 101.51% | 198.51% |
| Jul 11, 2022 | Leerink Partners | $10.00 | $3.35 | 198.51% | 273.13% |
The latest AC Immune SA stock forecast, released on May 30, 2024 by Thomas Shrader from BTIG, set a price target of $8.00, which represents a 101.51% increase from the stock price at the time of the forecast ($3.97), and a 198.51% increase from ACIU last price ($2.68).
AC Immune SA Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $8.00 |
| Last Closing Price | $2.68 | $2.68 | $2.68 |
| Upside/Downside | -100.00% | -100.00% | 198.51% |
In the current month, the average price target of AC Immune SA stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to AC Immune SA's last price of $2.68. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 30, 2024 | BTIG | Buy | Initialise | |
| Jul 11, 2022 | SVB Leerink | Outperform | Outperform | Hold |
AC Immune SA's last stock rating was published by H.C. Wainwright on Sep 18, 2024. The company gave ACIU a "Buy" rating, the same as its previous rate.
AC Immune SA Financial Forecast
AC Immune SA Revenue Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $1.00K | $3.93M | - | - | - | - | - | $944.00K | $1.12M | $1.28M | $12.41M | $1.06M | $33.41M | $1.51M | $75.04M | $1.46M | $2.01M | $1.33M |
| Avg Forecast | $180.99M | $531.47K | $7.20M | $90.89M | $5.34M | $15.29M | $50.07M | $2.50M | $1.60M | $349.15K | $350.82K | $28.15M | $631.68K | $1.77M | $3.41M | $769.57K | $425.00K | $199.47K | $12.82M | $1.77M | $31.01M | $1.17M | $98.07M | $1.53M | $1.89M | $1.18M |
| High Forecast | $180.99M | $703.09K | $7.20M | $90.89M | $5.34M | $16.56M | $50.07M | $2.50M | $1.60M | $349.15K | $350.82K | $28.15M | $631.68K | $1.77M | $3.41M | $769.57K | $425.00K | $199.47K | $12.82M | $1.77M | $31.01M | $1.17M | $98.07M | $1.84M | $2.27M | $1.42M |
| Low Forecast | $180.99M | $359.85K | $7.20M | $90.89M | $5.34M | $14.02M | $50.07M | $2.50M | $1.60M | $349.15K | $350.82K | $28.15M | $631.68K | $1.77M | $3.41M | $769.57K | $425.00K | $199.47K | $12.82M | $1.77M | $31.01M | $1.17M | $98.07M | $1.23M | $1.51M | $945.78K |
| # Analysts | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 7 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | 11.27% | - | - | - | - | - | 1.23% | 2.64% | 6.41% | 0.97% | 0.60% | 1.08% | 1.29% | 0.77% | 0.95% | 1.06% | 1.13% |
AC Immune SA's average Quarter revenue forecast for Jun 23 based on 1 analysts is $2.50M, with a low forecast of $2.50M, and a high forecast of $2.50M. ACIU's average Quarter revenue forecast represents a 250007.40% increase compared to the company's last Quarter revenue of $1.00K (Dec 22).
AC Immune SA EBITDA Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 7 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | $-18.03M | $-12.87M | $-18.23M | $-20.47M | $-15.10M | $-18.27M | $-16.16M | $-18.95M | $-18.45M | $-15.21M | $-7.16M | $-18.77M | $18.73M | $-16.00M | $65.06M | $-11.40M | $-7.72M | $-7.98M |
| Avg Forecast | $-57.88M | $-169.95K | $-2.30M | $-29.07M | $-1.71M | $-4.89M | $-16.01M | $-799.78K | $-511.45K | $-110.41K | $-17.40M | $-8.90M | $-199.76K | $-560.79K | $-16.70M | $-243.37K | $-134.40K | $-63.08K | $-8.69M | $-558.91K | $-9.81M | $-370.21K | $81.20M | $-11.95M | $-7.24M | $-6.98M |
| High Forecast | $-57.88M | $-115.07K | $-2.30M | $-29.07M | $-1.71M | $-4.48M | $-16.01M | $-799.78K | $-511.45K | $-110.41K | $-13.92M | $-8.90M | $-199.76K | $-560.79K | $-13.36M | $-243.37K | $-134.40K | $-63.08K | $-6.95M | $-558.91K | $-9.81M | $-370.21K | $97.44M | $-9.56M | $-5.79M | $-5.59M |
| Low Forecast | $-57.88M | $-224.83K | $-2.30M | $-29.07M | $-1.71M | $-5.30M | $-16.01M | $-799.78K | $-511.45K | $-110.41K | $-20.88M | $-8.90M | $-199.76K | $-560.79K | $-20.04M | $-243.37K | $-134.40K | $-63.08K | $-10.43M | $-558.91K | $-9.81M | $-370.21K | $64.96M | $-14.34M | $-8.69M | $-8.38M |
| Surprise % | - | - | - | - | - | - | - | - | 35.26% | 116.59% | 1.05% | 2.30% | 75.59% | 32.59% | 0.97% | 77.87% | 137.28% | 241.13% | 0.82% | 33.58% | -1.91% | 43.22% | 0.80% | 0.95% | 1.07% | 1.14% |
9 analysts predict ACIU's average Quarter EBITDA for Dec 19 to be $-558.91K, with a high of $-558.91K and a low of $-558.91K. This is -102.98% lower than AC Immune SA's previous annual EBITDA (Sep 19) of $18.73M.
AC Immune SA Net Income Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 7 | 9 |
| Net Income | - | - | - | - | - | - | - | - | $-18.75M | $-13.52M | $-18.85M | $-21.28M | $-15.92M | $-19.07M | $-16.73M | $-19.50M | $-18.99M | $-15.74M | $-7.69M | $-19.45M | $18.21M | $-16.90M | $63.57M | $-11.61M | $-9.46M | $-9.10M |
| Avg Forecast | - | $-17.71M | $-13.66M | $47.98M | $-13.66M | $-9.77M | $3.05M | $-19.63M | $-24.84M | $-22.84M | $-17.99M | $9.97M | $-26.90M | $-20.82M | $-16.73M | $-24.80M | $-24.54M | $-29.02M | $-9.34M | $-22.14M | $17.12M | $-22.01M | $79.34M | $-12.17M | $-8.86M | $-7.96M |
| High Forecast | - | $-16.10M | $-13.66M | $48.56M | $-13.66M | $-2.79M | $3.08M | $-19.63M | $-24.84M | $-22.84M | $-14.39M | $9.97M | $-26.90M | $-20.82M | $-13.39M | $-24.80M | $-24.54M | $-29.02M | $-7.47M | $-22.14M | $17.12M | $-22.01M | $95.20M | $-9.73M | $-7.09M | $-6.37M |
| Low Forecast | - | $-18.52M | $-13.66M | $47.40M | $-13.66M | $-16.74M | $3.02M | $-19.63M | $-24.84M | $-22.84M | $-21.59M | $9.97M | $-26.90M | $-20.82M | $-20.08M | $-24.80M | $-24.54M | $-29.02M | $-11.20M | $-22.14M | $17.12M | $-22.01M | $63.47M | $-14.60M | $-10.64M | $-9.56M |
| Surprise % | - | - | - | - | - | - | - | - | 0.75% | 0.59% | 1.05% | -2.13% | 0.59% | 0.92% | 1.00% | 0.79% | 0.77% | 0.54% | 0.82% | 0.88% | 1.06% | 0.77% | 0.80% | 0.95% | 1.07% | 1.14% |
AC Immune SA's average Quarter net income forecast for Dec 19 is $-22.14M, with a range of $-22.14M to $-22.14M. ACIU's average Quarter net income forecast represents a -221.54% decrease compared to the company's last Quarter net income of $18.21M (Sep 19).
AC Immune SA SG&A Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 7 | 9 |
| SG&A | - | - | - | - | - | - | - | - | $-2.25M | $3.27M | $4.17M | $-4.11M | $5.42M | $5.24M | $4.34M | $-2.47M | $4.89M | $4.16M | $4.50M | $-1.41M | $3.96M | $3.58M | $3.29M | $2.71M | $2.39M | $1.71M |
| Avg Forecast | $236.38M | $694.13K | $9.41M | $118.71M | $6.97M | $19.97M | $65.39M | $3.27M | $2.09M | $456.01K | $458.19K | $36.77M | $825.01K | $2.32M | $4.46M | $1.01M | $555.07K | $260.51K | $5.47M | $2.31M | $40.50M | $1.53M | $4.11M | $2.00M | $2.47M | $1.54M |
| High Forecast | $236.38M | $918.27K | $9.41M | $118.71M | $6.97M | $21.63M | $65.39M | $3.27M | $2.09M | $456.01K | $458.19K | $36.77M | $825.01K | $2.32M | $4.46M | $1.01M | $555.07K | $260.51K | $6.56M | $2.31M | $40.50M | $1.53M | $4.93M | $2.40M | $2.96M | $1.85M |
| Low Forecast | $236.38M | $469.98K | $9.41M | $118.71M | $6.97M | $18.31M | $65.39M | $3.27M | $2.09M | $456.01K | $458.19K | $36.77M | $825.01K | $2.32M | $4.46M | $1.01M | $555.07K | $260.51K | $4.38M | $2.31M | $40.50M | $1.53M | $3.29M | $1.60M | $1.98M | $1.24M |
| Surprise % | - | - | - | - | - | - | - | - | -1.08% | 7.18% | 9.09% | -0.11% | 6.57% | 2.26% | 0.97% | -2.45% | 8.81% | 15.95% | 0.82% | -0.61% | 0.10% | 2.34% | 0.80% | 1.35% | 0.97% | 1.11% |
AC Immune SA's average Quarter SG&A projection for Dec 22 is $2.09M, based on 1 Wall Street analysts, with a range of $2.09M to $2.09M. The forecast indicates a -36.20% fall compared to ACIU last annual SG&A of $3.27M (Sep 22).
AC Immune SA EPS Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 7 | 9 |
| EPS | - | - | - | - | - | - | - | - | $-0.22 | $-0.16 | $-0.23 | $-0.29 | $-0.22 | $-0.26 | $-0.23 | $-0.27 | $-0.26 | $-0.22 | $-0.11 | $-0.27 | $0.25 | $-0.24 | $0.94 | $-0.20 | $-0.17 | $-0.18 |
| Avg Forecast | - | $-0.18 | $-0.14 | $0.48 | $-0.14 | $-0.10 | $0.03 | $-0.19 | $-0.25 | $-0.23 | $-0.22 | $0.10 | $-0.27 | $-0.21 | $-0.23 | $-0.25 | $-0.25 | $-0.29 | $-0.08 | $-0.22 | $0.17 | $-0.22 | $1.21 | $-0.21 | $-0.15 | $-0.14 |
| High Forecast | - | $-0.16 | $-0.14 | $0.48 | $-0.14 | $-0.03 | $0.03 | $-0.19 | $-0.25 | $-0.23 | $-0.22 | $0.10 | $-0.27 | $-0.21 | $-0.23 | $-0.25 | $-0.25 | $-0.29 | $-0.08 | $-0.22 | $0.17 | $-0.22 | $1.21 | $-0.17 | $-0.12 | $-0.11 |
| Low Forecast | - | $-0.18 | $-0.14 | $0.47 | $-0.14 | $-0.17 | $0.03 | $-0.19 | $-0.25 | $-0.23 | $-0.22 | $0.10 | $-0.27 | $-0.21 | $-0.23 | $-0.25 | $-0.25 | $-0.29 | $-0.08 | $-0.22 | $0.17 | $-0.22 | $1.21 | $-0.25 | $-0.18 | $-0.16 |
| Surprise % | - | - | - | - | - | - | - | - | 0.89% | 0.70% | 1.04% | -2.90% | 0.81% | 1.24% | 1.00% | 1.08% | 1.05% | 0.75% | 1.41% | 1.22% | 1.45% | 1.09% | 0.78% | 0.95% | 1.13% | 1.33% |
According to 9 Wall Street analysts, AC Immune SA's projected average Quarter EPS for Dec 19 is $-0.22, with a low estimate of $-0.22 and a high estimate of $-0.22. This represents a -188.95% decrease compared to ACIU previous annual EPS of $0.25 (Sep 19).
AC Immune SA Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IVVD | Invivyd | $0.49 | $9.50 | 1838.78% | Buy |
| BDTX | Black Diamond Therapeutics | $2.50 | $20.00 | 700.00% | Buy |
| PEPG | PepGen | $4.30 | $29.50 | 586.05% | Buy |
| FDMT | 4D Molecular Therapeutics | $6.32 | $38.33 | 506.49% | Buy |
| AVTE | Aerovate Therapeutics | $2.56 | $13.00 | 407.81% | Hold |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| OPT | Opthea | $3.27 | $14.00 | 328.13% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| ANTX | AN2 Therapeutics | $1.34 | $5.00 | 273.13% | Buy |
| RGNX | REGENXBIO | $8.47 | $29.75 | 251.24% | Buy |
| ACRV | Acrivon Therapeutics | $7.21 | $22.50 | 212.07% | Buy |
| ACIU | AC Immune SA | $2.94 | $9.00 | 206.12% | Buy |
| PHVS | Pharvaris | $18.49 | $42.00 | 127.15% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| ABEO | Abeona Therapeutics | $5.88 | $6.00 | 2.04% | Buy |